Lightlake Therapeutics Inc. Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting

Published: Mar 27, 2013

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company’s Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

Back to news